MTRI InMed Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1728328 · Fiscal year ends 06/30
Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.7%
TTM net income YoY3.1%
TTM EPS YoY76.7%
Revenue 3-yr CAGR40.8%
Net income 3-yr CAGR—
Margins
Gross margin29.7%
Operating margin—
Net margin-170.1%
FCF margin—
EBITDA margin—
Returns
ROE-97.2%
ROA-77.8%
ROIC (approx.)—
Asset turnover0.46x
Leverage & solvency
Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | $4.94M |
| Cost of revenue | — | $3.24M |
| Gross profit | — | $1.71M |
| R&D expense | $3.03M | $2.82M |
| SG&A expense | $6.66M | $5.41M |
| Pretax income | -$11.37M | -$8.69M |
| Net income | -$12.56M | -$8.16M |
| EPS (basic) | -3.12 | -8.36 |
| EPS (diluted) | -3.12 | -8.36 |
| Weighted avg. shares (diluted) | 4.16M | 975,895 |
| Balance sheet | ||
| Cash & equivalents | $2.19M | $10.74M |
| Short-term investments | $39,670 | $43,384 |
| Receivables | — | $465,104 |
| Inventory | — | $961,173 |
| Current assets | $2.68M | $12.87M |
| PP&E, net | $221,037 | $992,199 |
| Intangibles | — | $1.62M |
| Total assets | $3.03M | $15.58M |
| Current liabilities | $1.96M | $1.84M |
| Total liabilities | $1.96M | $2.15M |
| Shareholders' equity | $1.08M | $13.43M |
| Shares outstanding | 5.34M | 2.00M |
| Cash flow statement | ||
| Operating cash flow | -$8.64M | -$8.10M |
| Financing cash flow | $94,496 | $12.27M |
| Depreciation & amortization | $205,271 | $212,839 |
| Stock-based compensation | $106,866 | $119,307 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.